Additional file 1: Table S1. of Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Investigator-assessed response across patient subgroups (efficacy-evaluable patients). Assessments and demographics for patients with metastatic BCC and locally advanced BCC. (DOCX 16 kb

Additional file 2: Table S2. of Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Most common TEAEs per 100 patient-years of exposure to vismodegib. TEAEs by type during vismodegib treatment for 1 year and after 12 months’ treatment. (DOCX 14 kb